Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer

被引：3

作者：

Mizuno, Nobumasa

Yamao, Kenji

Komatsu, Yoshito

Munakata, Masaki

Ishiguro, Atsushi

Yamaguchi, Taketo

Ohkawa, Shinichi

Kida, Mitsuhiro

Ioka, Tatsuya

Takeda, Koji

Kudo, Toshihiro

Kitano, Masayuki

Iguchi, Haruo

Tsuji, Akihito

Ito, Tetsuhide

Tanaka, Masao

Furuse, Junji

Hamada, Chikuma

Sakata, Yuh

机构：

[1] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Aichi 464, Japan

[2] Hokkaido Univ Hosp, Ctr Canc, Dept Canc Chemotherapy, Sapporo, Hokkaido, Japan

[3] Misawa City Hosp, Dept Med Oncol, Misawa, Japan

[4] Hirosaki Univ, Dept Med Oncol, Hirosaki, Aomori, Japan

[5] Chiba Canc Ctr, Div Gastroenterol, Chiba 2608717, Japan

[6] Kanagawa Canc Ctr Hosp, Hepatobiliary & Pancreat Oncol Div, Yokohama, Kanagawa, Japan

[7] Kitasato Univ, Sch Med, Dept Med, Sagamihara, Kanagawa 228, Japan

[8] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Hepatobiliary & Pancreat Oncol, Osaka, Japan

[9] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan

[10] Kinki Univ, Dept Med Oncol, Osaka, Japan

[11] Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osakasayama, Japan

[12] Natl Hosp Org, Shikoku Canc Ctr, Dept Gastroenterol, Matsuyama, Ehime, Japan

[13] Kochi Hlth Sci Ctr, Dept Med Oncol, Kochi, Japan

[14] Kyushu Univ, Dept Med & Bioregulatory Sci, Fukuoka 812, Japan

[15] Kyushu Univ, Dept Surg & Oncol, Fukuoka 812, Japan

[16] Kyorin Univ, Sch Med, Dept Internal Med, Mitaka, Tokyo 181, Japan

[17] Tokyo Univ Sci, Fac Engn, Tokyo 162, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期

关键词：

D O I：

10.1200/jco.2013.31.4_suppl.263

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

263

引用

页数：1

共 50 条

[41] Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study
Ioka, T.
Ikeda, M.
Ohkawa, S.
Yanagimoto, H.
Fukutomi, A.
Sugimori, K.
Baba, H.
Yamao, K.
Shimamura, T.
Chen, J.
Mizumoto, K.
Furuse, J.
Funakoshi, A.
Hatori, T.
Yamaguchi, T.
Egawa, S.
Sato, A.
Ohashi, Y.
Cheng, A.
Okusaka, T.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[42] Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
Kentaro Sudo
Takeshi Ishihara
Nobuto Hirata
Fumiaki Ozawa
Tadashi Ohshima
Ryosaku Azemoto
Kenji Shimura
Takeshi Nihei
Takayoshi Nishino
Akihiko Nakagawa
Kazuyoshi Nakamura
Taro Hara
Motohisa Tada
Rintaro Mikata
Katsunobu Tawada
Osamu Yokosuka
So Nakaji
Taketo Yamaguchi
Cancer Chemotherapy and Pharmacology, 2014, 73 : 389 - 396
[43] Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
Sudo, Kentaro
Ishihara, Takeshi
Hirata, Nobuto
Ozawa, Fumiaki
Ohshima, Tadashi
Azemoto, Ryosaku
Shimura, Kenji
Nihei, Takeshi
Nishino, Takayoshi
Nakagawa, Akihiko
Nakamura, Kazuyoshi
Hara, Taro
Tada, Motohisa
Mikata, Rintaro
Tawada, Katsunobu
Yokosuka, Osamu
Nakaji, So
Yamaguchi, Taketo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 389 - 396
[44] A phase II trial of gemcitabine, S-1 and LV combination therapy in patients with advanced pancreatic cancer
Saito, K. O.
Nakai, Y.
Isayama, H.
Ishigaki, K.
Saito, T.
Takahara, N.
Mizuno, S.
Kogure, H.
Koike, K.
ANNALS OF ONCOLOGY, 2018, 29
[45] Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report
Kishimoto, T.
Imamura, H.
Uedou, F.
Fujitani, K.
Iijima, S.
Takiuchi, H.
Imano, M.
Shimokawa, T.
Kurokawa, Y.
Furukawa, H.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[46] S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
Chen, Ye
Wu, Jing
Cheng, Ke
Li, Zhi-Ping
Luo, De-Yun
Qiu, Meng
Gou, Hong-Feng
Yi, Cheng
Li, Qiu
Wang, Xin
Yang, Yu
Cao, Dan
Shen, Ya-Li
Bi, Feng
Liu, Ji-Yan
ONCOLOGIST, 2019, 24 (05): : 591 - +
[47] Phase I study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy in gemcitabine-refractory pancreatic cancer patients.
Morizane, C.
Okusaka, T.
Furuse, J.
Ishii, H.
Ueno, H.
Ikeda, M.
Ogura, T.
Nakachi, K.
Suzuki, E.
EJC SUPPLEMENTS, 2007, 5 (04): : 272 - 273
[48] A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
Han, Boram
Kim, Bum Jun
Kim, Hyeong Su
Choi, Dae Ro
Shim, Byoung Yong
Lee, Kyung Hee
Kim, Jin Won
Kim, Jung Han
Song, Hunho
Kim, Jong Hyeok
Park, Choong Kee
Lee, Jung Woo
Kim, Min-Jeong
Zang, Dae Young
JOURNAL OF CANCER, 2021, 12 (03): : 912 - 917
[49] JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer
Fukutomi, Akira
Uesaka, Katsuhiko
Boku, Narikazu
Kanemoto, Hideyuki
Konishi, Masaru
Matsumoto, Ippei
Kaneoka, Yuji
Shimizu, Yasuhiro
Nakamori, Shoji
Sakamoto, Hirohiko
Morinaga, Soichiro
Kainuma, Osamu
Imai, Koji
Sata, Naohiro
Hishinuma, Shoichi
Nakamura, Takayuki
Kanai, Michio
Hirano, Satoshi
Yoshikawa, Yukinobu
Ohashi, Yasuo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[50] Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan
Fukutomi, Akira
Okusaka, Takuji
Sugimori, Kazuya
Ueno, Hideki
Ioka, Tatsuya
Ohkawa, Shinichi
Boku, Narikazu
Yamao, Kenji
Mizumoto, Kazuhiro
Furuse, Junji
Funakoshi, Akihiro
Hatori, Takashi
Yamaguchi, Taketo
Egawa, Shinichi
Sato, Atsushi
Ohashi, Yasuo
Cheng, Ann-Lii
Tanaka, Masao
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →